iBio price target raised to $6 from $5 at Oppenheimer

Oppenheimer raised the firm’s price target on iBio (IBIO) to $6 from $5 and keeps an Outperform rating on the shares, calling attention for IBIO-610 following updates from Wave Life Sciences’ (WVE) WVE-007 “well-deserved.” Wave’s initial Phase 1 INLIGHT efficacy and safety readout this quarter could provide mechanistic validation for iBio’s ‘601 and drive additional upside, the analyst tells investors.